The main objectives of “Automated
Patch Clamping Trends 2014” global benchmarking study was to comprehensively
document current practices, preferences and metrics in ion channel drug
screening using (Automated Patch Clamping) APC technology. It also seeks to
chart the emergence of new 384-well Automated Patch Clamping systems, what
determines Automated Patch Clamping consumable budgets, and most prevents
end-users making greater use of Automated Patch Clamping consumables. In
addition, a secondary focus was to understand respondents’ interests and
requirements in using a new Automated Patch Clamping technology for the
analysis of adherent cellular 2D networks. The survey collected 88 validated
responses, of these 63% provided comprehensive input. Survey responses were
geographically split: 34% North America; 31% Europe; 30% Japan; 2% China; 2%
Rest of World; and 1% India.
Complete Report
available at http://www.rnrmarketresearch.com/automated-patch-clamping-trends-2014-market-report.html
.
As per the report “Automated
Patch Clamping Trends 2014” The median annual APC consumable budget was
$50K-$100K/year today. Several bottom-up models were developed around the
respondent’s feedback to calculate the global Automated Patch Clamping markets.
In 2014 these were estimated to be around $140M for Automated Patch Clamping consumables
and $38M for new APC platforms. Segmentation & some CAGR estimates are in
the full report. The Automated Patch Clamping consumable budget for ion channel
testing of most respondents was not fixed i.e. it can be adjusted to reflect
cost changes per data point. The factors that most prevent greater use of APC
consumables today were the high cost of Automated Patch Clamping consumables
and lack of ion channel projects.
The report, available
for purchase @ http://www.rnrmarketresearch.com/contacts/purchase?rname=169011 , looked at the following aspects of ion channel
screening using Automated Patch Clamping technology, as practiced to date
(2014) and in some cases as predicted for the future (2016):
·
Ion channels classes of
greatest interest
·
Ion channels that have
proved most difficult to run as primary screens
·
Number of ion channel
programs investigated
·
Primary drivers for
initiating a new ion channel programs
·
Areas of drug discovery
applying Automated Patch Clamping technologies
·
Typical size of the
compound library in drug discovery areas using an Automated Patch Clamping
platform
·
Number of Automated
Patch Clamping patch wells expected to processed per year
·
Proportion of Automated
Patch Clamping assays using different cell types
·
Current access to Automated
Patch Clamping ion channel platforms
·
Preferred vendor’s APC
systems for different criteria
·
Likelihood of
purchasing a new Automated Patch Clamping platform over the next few years
·
Factors that most
influence a decision to purchase a particular APC platform
·
APC consumables budget
for ion channel screening and how they are determined
·
What factors most
prevent making greater use of Automated Patch Clamping consumables today
·
Whether the recent
introduction of new 384-well Automated Patch Clamping screening platforms will
affect screening activities
·
Prohibitive and
stimulative 384-well Automated Patch Clamping consumable price points
·
Awareness of the FDA
CIPA working group and its potential impact on safety assays undertaken. With
respect to a new Automated Patch Clamping system for adherent 2D cellular
networks the following were investigated: technologies already used to obtain
information on cell-cell communication within cellular 2D networks
·
What respondents most
want to analyze with the system
·
Applications most
suited to the system
·
Cell types most likely
to be used with the system
·
Main advantages of the
system
·
Impact of the potential
disadvantages of the system
·
Features essential for
the adoption and exploitation of the system
·
Optimal patch
combinations
·
Usefulness of the
potential throughput likely to be achieved with the system
·
Preferred routes to
access and fit to existing workflow of the system
·
Reasonable price to pay
for the Automated Patch Clamping system
·
Likelihood of future
purchasing of the system
Respondents represented:
20 Medium-Small Pharma; 17 University/ Research Institute/Government Labs/
Not-for-Profit; 16 Large Pharma; 15 Biotech Company; 9 Contract Research
Organisation; 6 Biopharma; 2 Academic Screening Center; 1
Agrochemical/Agri-Biotech Company; 1 Tobacco Company and 1 Other. Most survey
respondents had a senior job role or position which was in descending order: 20
research scientists/associates; 20 senior scientists/researchers; 12 principal
investigators; 9 section/group leaders; 5 post-docs; 5 department heads; 5
directors; 4 lab managers; 4 professors/assistant professors; 2 vice
presidents; and 2 others.
Survey results were
expressed as an average of all survey respondents. In addition, where
appropriate the data was reanalyzed after sub-division into the following 6
survey groups: 1) Pharma; 2) Other Screening Labs; 3) Academic Research; 4)
Europe; 5) North America; and 6) Japan.
